Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States

Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015;162(6):397-406.

Publication Type:

Journal Article

Authors:

Chhatwal, J.; Kanwal, F.; Roberts, M.S.; Dunn, M.A.

Source:

Ann Intern Med, Volume 162, Issue 6, p.397-406 (2015)

Keywords:

analysis, Fibrosis, Genotype, HCV, Health, hepatitis, Hepatitis C, hepatitis C virus, history, Infection, Life, Patients, Quality of Life, sofosbuvir, Standard of Care, therapy, Time, treatment, treatment-naive, United States

Cited On:

Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25775312

Export Citation:

RIS Format

Top